Agilent breaks ground on $725 million Colorado manufacturing expansion
Agilent Technologies has begun a $725 million expansion of its manufacturing facility in Frederick, Colorado. The investment is expected to create over 160 life science jobs and double the production capacity for nucleic acid therapeutics.
Agilent Technologies commenced a significant expansion of its manufacturing operations in Frederick, Colorado, with a $725 million investment. Colorado Governor Jared Polis joined company officials for the groundbreaking ceremony of the project, which aims to double Agilent's manufacturing capacity for therapeutic nucleic acids.
The expansion is projected to create more than 160 new life science jobs in the Frederick area. The investment also aims to bolster U.S. domestic manufacturing of active pharmaceutical ingredients (API) crucial for treating diseases such as cancer, cardiovascular conditions, and rare and infectious diseases.
Agilent's Colorado facility produces molecules including siRNA, antisense, and CRISPR guide RNA. The company provides contract development and manufacturing services for these therapeutic nucleic acids, covering the entire process from early-stage clinical development to commercialization, with an emphasis on quality and efficiency.
The expansion is anticipated to be completed by the end of 2026. Additionally, Agilent announced a $25,000 donation to P-TECH, a local high school program supporting students from underrepresented communities pursuing life science education.